Small cap Natural Grocers by Vitamin Cottage (NYSE: NGVC) and mid cap Sprouts Farmers Market Inc (NASDAQ: SFM) are taking aim at natural and organic foods supermarket giant Whole Foods Market (NASDAQ: WFM), but do either of these stocks have what it takes to take on the the king of organic retailing? Whole Foods Market was founded in Austin way back in 1978 by a�twenty-five year old college dropout and a twenty-one year old�at a time when there were only a handful of natural or organic�supermarkets in the country. Today, Whole Foods Market�has 364 stores in the United States, Canada and the United Kingdom���which are sometimes referred to as ��hole Wallet��r ��hole Paycheck��given how much it costs to shop there.
However, Whole Foods Market is not the only natural or organic focused supermarket chain hoping to take your ��hole wallet��or ��hole paycheck:��/p>
Top 5 Long Term Companies To Watch In Right Now: MFC Industrial Ltd (MIL)
MFC Industrial Ltd., formerly Terra Nova Royalty Corp., is a global commodity supply chain company that sources and delivers commodities and materials to clients all over the world. The Company is engaged in the financing and risk management aspect of the business. The Company operates in three segments: commodities and resources, which includes its commodities activities and mineral interests; merchant banking, which includes structured solutions, logistics and financial services and investing activities, and other, which encompasses its corporate and other investments and business interests, including its medical supplies and servicing business. In December 2011, the Company acquired Pea Ridge Iron Ore Mine in Missouri, the Unites States of America. In September 2012, its indirect wholly owned subsidiary acquired the remaining interest in Compton Petroleum Corporation. In November, 2012, it acquired 70% interest in Park Ridge, NJ-based ACC Resources Co., L.P. (ACCR) and 60% interest in Mexico City-based Possehl Mexico S.A. de C.V. (Possehl). In April 2013, 0915988 BC Ltd acquired the entire share capital of MFC Industrial Ltd.
Commodities and Resources
The Company�� supply chain business is globally focused and includes its integrated commodities operations and its mineral interests. It conducts such operations primarily through its subsidiaries based in Vienna, Austria and supply various commodities, including minerals and metals, chemicals, plastics and wood products to its customers. Through its global commodity supply chain business, it also provides logistics, supply chain management and other services to producers and consumers of commodities. Its commodities operations include sourcing and supplying commodities. The Company sources its commodities from Asia, Africa, Europe, Australia, the United States and the Middle East. Its commodities sales include the European, Middle Eastern, Asian and North and South American markets.
Merchant Banking
The Company�� merchant banking operations include merchant banking and financial services, specialized banking, third-party financing and other services, investing and its real property. Its activities include making investments through investing its own capital to capture investment opportunities. The Company focuses on meeting the financial needs of small to mid-sized companies and other business enterprises primarily in Europe and Asia. Its merchant banking business generates revenues in the form of corporate and trade finance service fees and interest income. It also realizes gains from time to time on its investments, upon their sale, the execution of an equity or debt .
Other
Its other segment include its corporate and other investments, It includes financing joint ventures through its Shanghai, China-based subsidiary which provides medical services, equipment and supplies.
Advisors' Opinion:- [By Tim Melvin]
Just last week I went around the world with a stock screener to see if any cheap and appealing stocks appeared. At the top of my international buy list right now is Canada-based�MFC Industrial (MIL). MIL has also shown up on my screen for “perfect stocks” since it trades below book value, is profitable and pays a dividend.
- [By Rich Duprey]
Global commodity supply chain company�MFC Industrial (NYSE: MIL ) announced yesterday its third-quarter dividend of $0.06 per share, the same rate it's paid for the past year.
5 Best Supermarket Stocks To Invest In 2014: Maui Land & Pineapple Company Inc. (MLP)
Maui Land & Pineapple Company, Inc., together with its subsidiaries, engages in the development, sale, and leasing of real estate properties. It owns approximately 23,300 acres of land on Maui. The company also offers water and waste transmission services. In addition, it manages certain resort amenities at the Kapalua Resort. The company was founded in 1909 and is based in Lahaina, Hawaii.
Advisors' Opinion:- [By Dividends4Life]
Sunoco Logistics Partners (SXL) is a master limited partnership (MLP) that was formed by Sunoco Inc. to acquire, own and operate a group of refined product and crude oil pipelines and terminal facilities.
Yield: 3.6% | Years of Dividend Growth: 11 - [By Matthew Skelly]
The technology of fracturing (and the horizontal style of drilling), is changing America's needs on the energy front. At the epicenter of this infrastructure build-out is Atlas Pipeline Partners (NYSE:APL), a midstream gathering and processing company that trades as a Master Limited Partnership, (MLP). Atlas Pipeline is essentially a middle man between the drillers and long-haul transportation pipelines. It gathers mixed volumes of natural gas and natural gas liquids (NGLs) such as ethane, propane, and butanes, etc. from the thousands of wells drilled by its drilling customers, back through pipelines to its processing plants, which will separate the gas from the NGLs. Both are then sold to long-haul transportation pipelines, which take the two products downstream to the next part of the energy supply chain.
5 Best Supermarket Stocks To Invest In 2014: Blackrock Corporate High Yield Fund Inc (HYT)
BlackRock Corporate High Yield Fund VI, Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income by investing primarily in a diversified portfolio of fixed-income securities.
The investments are rated in the lower rating categories of the rating services (Ba or lower by Moody's Investors Service, Inc., or BB or lower by Standard & Poor's Corporation) or are unrated securities of comparable quality. BlackRock Advisors, LLC. is the manager of the Fund.
Advisors' Opinion:- [By Aaron Levitt]
MMT comes with a hefty 6.76% distribution yield and is currently trading for a nearly 12% discount to its underlying value. That�� well over the normal discount range for the fund. �Expenses for MMT run 1.00% — or $100 per $10,000 invested — per year.
BlackRock Corporate High Yield Fund (HYT)Discount to NAV: 7.11%
Distribution Yield: 7.86%
5 Best Supermarket Stocks To Invest In 2014: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By Dan Carroll]
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan (NASDAQ: MYL ) , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more than 15% in the past month alone.
- [By Ben Levisohn]
Mylan (MYL) wants to start preparing a generic version of two Celegene (CELG) drugs. Celegene obviously wants to make that as difficult as possible. And now they’re heading to court.
Reuters has the details on Mylan’s lawsuit against Celgene:
In its lawsuit filed in the U.S. District Court in Newark, New Jersey, Mylan accused Celgene of using federal limits on the distribution of Revlimid and Thalomid, which were designed to promote the drugs’ safety, as a pretext to keep generic drug makers from obtaining their own samples…
The lawsuit seeks to force Celgene to sell Mylan enough Revlimid and Thalomid at market prices to allow for bioequivalence testing. It also seeks compensation for Mylan’s inability to sell generic versions of both, and triple damages.
Barclays’ Ying Huang and team believe the odds favor Celgene over Mylan:
It is our understanding that [Celgene] has no obligation to provide samples of Revlimid to generic manufacturers. The Risk Evaluation and Mitigation Strategies (REMS) program required by the FDA for Revlimid also makes it difficult to obtain the product on the open market. Patients and physicians are required under REMS to register in a database administered by�[Celgene] before Revlimid is distributed. We note the REMS program argument has been upheld by the court in previous generic litigation cases.
Shares of Celgene have dropped 4.1% to $137.79 at 2:28 p.m., while Mylan has gained 2.3% to $51.02.
No comments:
Post a Comment